Thus, pathologic cardiac hypertrophy is associated with decreased cellular NAD+ levels, and supplementation with NAD+ activates cardiac SIRT3 and blocks ANGII-induced hypertrophy. Here, SIRT3 is linked to cardiac hypertrophy.